Related Experiment Video
Updated: Jun 7, 2026
13:57
Bio-layer Interferometry for Measuring Kinetics of Protein-protein Interactions and Allosteric Ligand Effects
Published on: February 18, 2014
Hit-to-Lead Optimization of Energy-Coupling Factor (ECF) Transporter Inhibitors as Novel Antibiotic
Ioulia Exapicheidou1,2, Aleksei Tsarenko3, Lena Zeller1,2
1Helmholtz Institute for Pharmaceutical Research (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus Building E 8.1, Saarbrücken, Saarland D-66123, Germany.
Journal of Medicinal Chemistry
|June 6, 2026
Summary
New inhibitors targeting energy-coupling factor (ECF) transporters show promising results. Optimized compounds demonstrate potent antibacterial activity and efficacy in vivo, offering potential new treatments against antimicrobial resistance.
Area of Science:
- Biochemistry and Medicinal Chemistry
- Antimicrobial Drug Discovery
Background:
- Energy-coupling factor (ECF) transporters are crucial for nutrient uptake and represent a target for combating antimicrobial resistance.
- Previous research identified a class of ECF transporter inhibitors, but their drug-like properties required improvement.
Purpose of the Study:
- To optimize a class of ECF transporter inhibitors by enhancing their drug-like properties and confirming in vivo efficacy.
- To explore structure-activity relationships around a specific region of the lead molecule using click chemistry.
Main Methods:
- Focused structure-activity relationship study utilizing click chemistry.
- Multiparameter optimization of lead compounds.
- In vitro testing against Gram-positive bacteria and ECF transporters.
- In vivo efficacy studies in Galleria mellonella and Danio rerio infection models.
Main Results:
- Optimized compounds exhibited improved metabolic stability and solubility.
- Potent activity was observed against a panel of Gram-positive bacteria and ECF transporters.
- Rapid bacterial killing was demonstrated in vitro, and in vivo efficacy was confirmed in animal models.
Conclusions:
- The optimized inhibitors show significant therapeutic potential for treating bacterial infections.
- This work validates ECF transporters as viable targets for antimicrobial drug development.
- The developed compounds represent promising leads for further investigation against antimicrobial resistance.
Related Concept Videos
01:27Combined Effects of Drugs: Synergism
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
01:31ABC Transporters: Exporter
ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
01:25Inhibitors of Bacterial Protein Synthesis
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
00:57Antibiotic Selection
Overview
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:27Production of Antibiotics
Penicillin, one of the earliest and most widely used antibiotics, is produced industrially by the filamentous fungus Penicillium chrysogenum. Large stirred-tank bioreactors ranging from tens to hundreds of thousands of liters maintain tightly controlled temperature, pH, and dissolved oxygen conditions to support fungal metabolism and maximize antibiotic yield. Penicillin is a secondary metabolite, synthesized primarily during the stationary growth phase, which requires a carefully managed...